tiprankstipranks
Trending News
More News >
Sensei Biotherapeutics (SNSE)
NASDAQ:SNSE

Sensei Biotherapeutics (SNSE) AI Stock Analysis

Compare
209 Followers

Top Page

SN

Sensei Biotherapeutics

(NASDAQ:SNSE)

Rating:40Underperform
Price Target:
Sensei Biotherapeutics faces substantial financial challenges, with no revenue and ongoing net losses. The technical analysis indicates a bearish trend, and the valuation is poor due to negative earnings. However, the positive corporate event regarding trial results offers a glimpse of potential future success. The overall score reflects these mixed factors, with financial weaknesses being the most significant deterrent.
Positive Factors
Analyst Recommendation
Analyst reiterates a Buy rating for Sensei Biotherapeutics with a price target of $4, based on probability-adjusted revenue forecasts for SNS-101.
Clinical Trial Results
Sensei Biotherapeutics has reported compelling preliminary dose expansion data for solnerstotug in patients with advanced solid tumors, showing a high disease control rate.
Therapeutic Approval Potential
SNS-101 could potentially be the first anti-VISTA monoclonal antibody approved as a therapeutic agent, with an anticipated launch in 2029.
Negative Factors
Earnings Performance
Sensei reported 4Q24 EPS of ($0.31), compared to an estimate of ($0.29).
Efficacy in Specific Patient Groups
No complete or partial responses were observed in patients with 'cold' tumors, as expected, indicating limited efficacy in this group.
Financial Projections
Decreasing FY25 EPS estimate to ($0.94) from ($0.76).

Sensei Biotherapeutics (SNSE) vs. SPDR S&P 500 ETF (SPY)

Sensei Biotherapeutics Business Overview & Revenue Model

Company DescriptionSensei Biotherapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of immunotherapies with an initial focus on treatments for cancer. It develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response; and Tumor Microenvironment Activated Biologics, a platform designed to unleash the anti-tumor potential of T-cells, as well as human monoclonal antibodies that are selectively active in the tumor microenvironment and target immune checkpoints or other critical immune pathways. The company also develops SNS-101, a monoclonal antibody for the treatment of cancer; and SNS-401-NG, an ImmunoPhage vaccine targeting multiple tumor antigens. It has a collaboration with The University of Washington to research and develop Merkel cell carcinoma vaccine. The company was formerly known as Panacea Pharmaceuticals, Inc. Sensei Biotherapeutics, Inc. was incorporated in 1999 and is headquartered in Rockville, Maryland.
How the Company Makes MoneySensei Biotherapeutics makes money primarily through the development and potential commercialization of its proprietary immunotherapy products. The company's revenue model is centered around advancing its product candidates through clinical trials, with the ultimate goal of gaining regulatory approval for commercialization. Key revenue streams may include licensing agreements, collaborations, and partnerships with larger pharmaceutical companies, which can provide upfront payments, milestone payments, and royalties on future sales of their developed therapies. Additionally, Sensei may secure funding through grants and research collaborations that support its R&D efforts. However, as a clinical-stage company, Sensei is primarily focused on research and development activities and may not yet have significant product sales revenue.

Sensei Biotherapeutics Financial Statement Overview

Summary
Sensei Biotherapeutics faces significant financial challenges, primarily due to a lack of revenue and ongoing net losses. While there are some improvements in the balance sheet, such as reduced debt levels, the overall financial health is weak with negative cash flows and profitability metrics. The company needs to focus on revenue generation and operational efficiency to improve its financial standing.
Income Statement
15
Very Negative
Sensei Biotherapeutics has not generated any revenue over the past years, which is a significant concern. The company has consistently reported net losses, indicating ongoing challenges in achieving profitability. The EBIT and EBITDA margins are negative, reflecting operational inefficiencies and high operational costs relative to nonexistent revenue.
Balance Sheet
40
Negative
The company's balance sheet shows a moderate level of debt with a debt-to-equity ratio that has improved over time due to a reduction in liabilities and an increase in equity. However, the negative net income impacts the return on equity, and the equity ratio is under pressure due to declining total assets. The improvement in net debt indicates better cash management, but the overall equity position remains weak.
Cash Flow
30
Negative
Operating cash flow is negative, indicating that the company is not generating sufficient cash from its core operations. Free cash flow is consistently negative, which could pose liquidity challenges. The company has been reliant on financing activities to sustain operations, which is not sustainable in the long term without revenue generation.
Breakdown
TTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income StatementTotal Revenue
0.000.000.000.000.000.00
Gross Profit
-135.00K0.00-571.00K-1.81M-685.00K-209.00K
EBIT
-31.16M-32.61M-37.06M-50.19M-37.48M-19.45M
EBITDA
-28.77M-32.61M-33.39M-46.56M-36.80M-18.50M
Net Income Common Stockholders
-29.03M-30.16M-34.10M-48.81M-37.46M-20.63M
Balance SheetCash, Cash Equivalents and Short-Term Investments
34.33M41.34M65.76M17.80M147.62M16.60M
Total Assets
38.27M45.36M74.37M118.38M153.22M21.43M
Total Debt
3.21M3.85M6.21M8.03M2.35M567.00K
Net Debt
-6.67M-6.15M-6.80M-9.76M-4.80M-16.03M
Total Liabilities
6.29M6.97M9.48M14.97M6.71M77.87M
Stockholders Equity
31.99M38.39M64.89M103.41M146.51M-56.44M
Cash FlowFree Cash Flow
-24.26M-24.82M-32.20M-39.35M-32.28M-18.91M
Operating Cash Flow
-24.15M-24.67M-32.02M-39.03M-30.26M-17.70M
Investing Cash Flow
23.86M22.44M38.41M49.95M-143.12M-1.40M
Financing Cash Flow
-792.00K-787.00K-11.17M-287.00K163.94K35.45M

Sensei Biotherapeutics Technical Analysis

Technical Analysis Sentiment
Positive
Last Price6.55
Price Trends
50DMA
7.08
Positive
100DMA
8.00
Negative
200DMA
9.13
Negative
Market Momentum
MACD
-0.07
Negative
RSI
57.80
Neutral
STOCH
61.01
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SNSE, the sentiment is Positive. The current price of 6.55 is above the 20-day moving average (MA) of 6.52, below the 50-day MA of 7.08, and below the 200-day MA of 9.13, indicating a neutral trend. The MACD of -0.07 indicates Negative momentum. The RSI at 57.80 is Neutral, neither overbought nor oversold. The STOCH value of 61.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SNSE.

Sensei Biotherapeutics Risk Analysis

Sensei Biotherapeutics disclosed 67 risk factors in its most recent earnings report. Sensei Biotherapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks

Sensei Biotherapeutics Peers Comparison

Overall Rating
UnderperformOutperform
Sector (54)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
54
Neutral
$5.25B3.27-44.35%6.27%16.79%-0.10%
51
Neutral
$3.37M-205.75%2552.29%60.70%
49
Neutral
$15.80M-92.35%-85.48%45.13%
GRGRI
45
Neutral
$3.19M-468.00%98.55%
41
Neutral
$23.50M-160.26%19.21%
40
Underperform
$164.36M-64.18%1.00%
36
Underperform
$12.51M-110.70%18.61%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
SNSE
Sensei Biotherapeutics
7.48
-4.66
-38.39%
RLMD
Relmada Therapeutics
0.70
-2.34
-76.97%
ATHA
Athira Pharma
0.31
-1.98
-86.46%
EVAX
Evaxion Biotech
2.17
-11.38
-83.99%
GRI
GRI Bio
1.40
-41.27
-96.72%
SABS
SAB Biotherapeutics
1.78
-0.99
-35.74%

Sensei Biotherapeutics Corporate Events

Product-Related AnnouncementsBusiness Operations and Strategy
Sensei Biotherapeutics Reports Promising Phase 1/2 Trial Results
Positive
Mar 27, 2025

On March 27, 2025, Sensei Biotherapeutics announced favorable preliminary results from the dose expansion portion of its Phase 1/2 trial for solnerstotug, a monoclonal antibody targeting VISTA, in PD-(L)1 resistant tumors. The trial showed an overall response rate nearly three times higher than historical PD-(L)1 rechallenge rates, with notable responses observed in Merkel Cell Carcinoma and MSI-H Colorectal Cancer patients. These findings suggest solnerstotug may offer a significant clinical benefit in select tumor types. The company plans to initiate a Phase 2 study in early 2026, contingent on securing sufficient capital, with ongoing analyses to optimize trial design and patient selection.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.